Onc.AI
PrivateLast Round
Grant
Oct 24, 2024
Total Funding Raised
$33M
Company Overview
Onc.AI operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Grant round in October 2024.
Onc.AI is a digital health company that develops AI-driven oncology clinical management solutions using deep learning to analyze diagnostic imaging for precision cancer care.
Sector
Healthcare & Life Sciences
Verticals
Medical Imaging, Medical AI, Precision Medicine, Clinical Trials, Healthcare Analytics
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Onc.AI Comparables
Compare Onc.AI with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Optellum | 76% | |
| ArteraAI | 75% | |
| OncoHost | 74% |
For institutional investors. Book with your work email.
Onc.AI Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 24, 2024 | ||||
| Series A | Jan 5, 2023 | ||||
| Seed | Dec 3, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Onc.AI Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KF Ventures | Series A |
| National Cancer Institute | Grant |
| Digitalis Ventures | Seed, Series A |
| LifeX Ventures | Series A |
| 515 Ventures | Seed |
| Action Potential Venture Capital | Series A |
| Accomplice | Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 12, 2026
Developing AI for faster detection of rare and complex cancers.
- May 30, 2025
Will present deep learning radiomic biomarker results at 2025 ASCO Annual Meeting.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 21, 2026
Onc.Ai, Inc. develops Onclara Evaluate to analyze CT scans taken before and during treatment, estimate survival probability, and stratify patients by risk for clinical oncology and pharmaceutical research.
For institutional investors. Book with your work email.
Onc.AI Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Onc.AI's valuation, stock price, and market status.
Is Onc.AI a public or private company?
Onc.AI is a private company.
What is the current stock price of Onc.AI?
Onc.AI is a private company, so its shares have no public market price. Caplight tracks Onc.AI's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Onc.AI worth (valuation)?
Valuation information for Onc.AI is not publicly available.
Can I buy Onc.AI stock?
Onc.AI shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Onc.AI's last funding round?
Onc.AI's most recent funding round was Grant on October 24, 2024.
Who are the main investors in Onc.AI?
Key investors in Onc.AI include Action Potential Venture Capital, Accomplice, Blue Venture Fund, Sandbox Industries.
Will Onc.AI IPO soon?
No public IPO plans have been announced for Onc.AI.
How can I track Onc.AI secondary market activity?
Caplight tracks bids, offers, and trades in Onc.AI's shares on secondary markets.